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ABSTRACT 
Most high-grade serous carcinomas are thought to arise from Fallopian tube epithelium (FTE), 
but some likely arise outside of the tube, perhaps from ectopic tubal-type epithelium known as 
endosalpingiosis. Importantly, the origin of endosalpingiosis is poorly understood. The proximity 
of the tubal fimbriae to the ovaries has led to the proposal that disruptions in the ovarian 
surface that occur during ovulation may allow detached FTE to implant in the ovary and form 
tubal-type glands and cysts.  An alternative model suggests that cells present in ectopic 
locations outside the Müllerian tract retain the capacity for multi-lineage differentiation and can 
form glands with tubal-type epithelium.  We used double transgenic Ovgp1-iCreERT2;R26RLSL-
eYFP mice, which express an eYFP reporter protein in OVGP1-positive tissues following transient 
tamoxifen (TAM) treatment, to track the fate of oviductal epithelial cells.   Cohorts of adult mice 
were given TAM to activate eYFP expression in oviductal epithelium, and ovaries were 
examined at time points ranging from 2 days to 12 months post-TAM.  To test whether 
superovulation might increase acquisition of endosalpingiosis, additional cohorts of TAM-
treated mice underwent up to five cycles of superovulation and ovaries were examined at 1 
month, 6 months, and 12 months post-TAM.  Ovaries were sectioned in their entirety to identify 
endosalpingiosis.  Immunohistochemical staining for PAX8, Tubulin, OVGP1, and eYFP was 
employed to study endosalpingiosis lesions.  
 
Ovarian endosalpingiosis was identified in 14.2 % of TAM-treated adult mice.  The 
endosalpingiotic inclusion glands and cysts were lined by secretory and ciliated cells and 
expressed PAX8, tubulin, OVGP1 and eYFP.  Neither age nor superovulation was associated 
with a significant increase in endosalpingiosis.  Endosalpingiosis was also occasionally present 
in the ovaries of pre-pubertal mice. The findings imply that ovarian endosalpingiosis in the 
mouse does not likely arise as a consequence of detachment and implantation of tubal 
epithelium and other mechanisms may be relevant.   
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High-grade serous carcinoma (HGSC), the most common and lethal type of “ovarian” cancer, is 
now believed to arise most often from Fallopian tube epithelium (FTE), preferentially in the 
tubal fimbriae [1-5].  However, upwards of one-third of HGSCs lack evidence of FT origin, even 
after exhaustive microscopic examination of the FTs in women with presumptive ovarian or 
peritoneal primaries [6].  For example, in their comprehensive review of reports of occult 
cancers identified in women with hereditary predisposition for ovarian cancer who underwent 
prophylactic risk-reducing surgery, Yates and colleagues found that 60.5% were confined to the 
FTs, whereas 21.1% involved only the ovary and 2.6% involved only the peritoneum [7].  These 
studies suggest that some HGSCs indeed arise outside of the FT mucosa (endosalpinx).  
Given the absence of data indicating that tubal HGSCs are molecularly or biologically distinct 
from HGSCs arising in the ovary or peritoneum, it is reasonable to suspect that the latter 
tumors also arise from FT-like epithelium, albeit in an ectopic location.  Endosalpingiosis 
(ectopic tubal-type epithelium) is a benign entity comprised of the cell types, including ciliated 
and secretory cells, present in normal FTE [8].  It represents a plausible source of cells that 
undergo malignant transformation to HGSC in those cases lacking precursor lesions in the 
tubal fimbriae. 
   
Surprisingly little is known about the origins of endosalpingiosis, and our current understanding 
is based largely on retrospective analyses of surgical specimens removed for unrelated 
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indications.  From these observations have emerged two alternative, but not mutually-exclusive 
models to explain the origin of endosalpingiosis. In the “tubal escape” model, 
the close proximity of the tubal fimbriae to the ovarian surface has led to the proposal that 
disruptions in the ovarian surface epithelium (OSE) that occur during ovulation allow dislodged 
FTE from the fimbriae to be implanted in the ovary and form inclusion cysts and glands lined by 
tubal-type epithelium [8,9].  Detached FTE might also be exposed to cytokines released during 
ovulation that attract the cells to the ovary and support their implantation.  The “Müllerian 
metaplasia” model suggests latent cells present in ectopic locations outside the Müllerian tract 
retain the capacity for multi-lineage differentiation and can reconstitute simple glands with 
“normal” tubal-type epithelium [8,10]. 
 
Importantly, “opportunistic” bilateral salpingectomy and salpingectomy as an alternative to 
conventional tubal ligation for sterilization have been recommended in Canada and the United 
States to reduce HGSC risk in women without known hereditary risk [11]. In addition, for 
women with hereditary ovarian cancer risk, a staged approach (salpingectomy with delayed 
oophorectomy) for risk reduction is being evaluated [12,13].  Each of these cancer prevention 
strategies relies on the underlying assumption that most HGSCs have a tubal origin.  Given 
existing data supporting the non-tubal origin of at least some HGSCs, it is important to develop 
a better understanding of the origins of endosalpingiosis and its potential to undergo malignant 
transformation. 
 
Ovarian endosalpingiosis-like lesions in mouse ovaries have been reported by several groups 
[14–17].  Genetically engineered mice provide an opportunity to use lineage tracing to monitor 
the fate of oviductal epithelial cells (equivalent to human FTE) over time, and hence, to 
determine whether ectopic tubal-type epithelium (e.g., ovarian endosalpingiosis) likely arises as 
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a consequence of detachment and implantation in locations outside of the oviducts.  The 
mouse and human anatomy differ in that, in the mouse, the ovaries lie within a membranous 
pouch (bursa) that isolates them from the peritoneal cavity.   The fimbriated end of the oviduct 
opens into the bursal cavity.  Hence, epithelial cells detaching from the distal oviduct cannot 
easily leave the bursa, have direct access to the ovarian surface, and would be predicted to 
preferentially implant in the adjacent ovary, particularly if there are breaks in the OSE.  OVGP1 
is strongly expressed by murine oviductal epithelium, but not by the OSE or cells in the ovarian 
stroma, and can therefore be considered an excellent marker of tubal differentiation, at least in 
the mouse [18].  We have recently developed Ovgp1-iCreERT2 mice in which oviduct-specific 
Cre-mediated recombination in OVGP1-expressing cells can be induced with transient 
treatment with Tamoxifen (TAM) [18].  We have also generated double transgenic Ovgp1-
iCreERT2;R26LSL-eYFP mice in which Cre-inducible eYFP reporter expression can be used to 
monitor the fate of oviductal epithelial cells in TAM-treated mice.   
 
In this study we sought to directly address some key predictions of the proposed models for 
endosalpingiosis. Specifically, if disruption of the OSE during ovulation allows implantation of 
detached oviductal epithelium (i.e., “tubal escape”) is the dominant mechanism, 
OVGP1+/eYFP+ endosalpingiosis lesions should increase with age and with increased 
ovulatory events.  In order to test these predictions, we assessed the frequency of 
endosalpingiosis in the ovaries of TAM-treated double transgenic Ovgp1-iCreERT2;R26LSL-eYFP 
mice at intervals over 12 months, and in the presence and absence of superovulation.     
 
MATERIALS AND METHODS 
Genetically engineered mice and animal care  
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Procedures involving mice for the research described herein have been approved by the 
University of Michigan’s Institutional Animal Care and Use Committee (PRO00006370 and 
PRO00008343).  The development and characterization of Ovgp1-iCreERT2 transgenic mice 
and Ovgp1-iCreERT2 transgenic mice crossed with reporter mice carrying the 
Gt(ROSA)26Sortm1(EYFP)Cos/J allele, hereafter referred to as R26RLSL-eYFP (Jackson Laboratory, 
Bar Harbor, ME, USA) have been described in detail [18].  The Ovgp1-iCreERT2;R26RLSL-eYFP 
double transgenic mice were maintained on a mixed genetic background and monitored daily.  
Mouse genotypes were confirmed by PCR analysis of tail-derived DNA. For all studies, only 
Ovgp1-iCreERT2;R26RLSL-eYFP double transgenic mice were used.  
 
In vivo induction of eYFP expression   
6-8 wk old Ovgp1-iCre-ERT2;R26RLSL-eYFP female mice were given intraperitoneal injections of 
TAM (Sigma-Aldrich, St. Louis, MO) to activate Cre recombinase activity, and hence, eYFP 
reporter expression in OVGP1 expressing cells/tissues. TAM was first dissolved in 100% 
ethanol to a concentration of 400 mg/ml, and then diluted in corn oil to a concentration of 20 




Cohorts of 6-8 wk old female mice were superovulated as previously described [19]. In brief, 
mice were given 5 IU pregnant mare serum gonadotropin (PMSG, Sigma-Aldrich) by 
intraperitoneal injection, followed by 5 IU human chorionic gonadotropin (HCG, Sigma-Aldrich) 
intraperitoneally 48 h later.  This cycle was initiated 5-7 days following TAM injection and 
repeated every two weeks for a maximum of 5 cycles.  Superovulated mice were sacrificed at 
intervals 1 mo, 6 mo, or 12 mo post-TAM.   
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Histopathology and Immunohistochemistry  
Ovarian and oviductal tissues were fixed in 10% buffered formalin, paraffin-embedded, and 
serially sectioned (5 µm) in their entirety. Hematoxylin and eosin staining was used to examine 
the morphology of every third section by routine light microscopy. If any suspected 
endosalpingiosis lesions were observed, then immunohistochemical (IHC) staining of adjacent 
sections was used to assess expression of eYFP and OVGP1 in the lesions, with OVGP1 
expression confirming tubal-type differentiation in the cells of interest, and eYFP expression 
indicating their origin from OVGP1 positive cells (presumptively from the FT).  
Immunohistochemical staining for OVGP1 and PAX8 was also used to study extra-ovarian rete, 
and in selected cases to clarify the identity of cysts observed near the ovarian hilum.  IHC was 
performed using standard methods as described previously [18].  Primary antibodies used were 
goat anti-mouse OVGP1 polyclonal antibody (1:500, Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA), rabbit anti-mouse GFP monoclonal antibody – also detects YFP expression 
(1:500, Cell Signaling, Danvers, MA, USA), rabbit anti-mouse PAX8 polyclonal antibody (1:750, 
Novus Biologicals, Englewood, CO, USA), and mouse anti-mouse tubulin monoclonal antibody 
(1:1000, Sigma-Aldrich).  The Mouse on Mouse Detection Kit (Elite Peroxidase, Vector Labs, 
Burlingame, CA, USA) was used for IHC detection of tubulin following the manufacturer’s 
instructions.   
 
Statistics 
The incidence of ovarian endosalpingiosis lesions in mice 2d post-TAM was compared to mice 
at later time points using the two-tailed Fisher’s exact test.  Mantel-Haenszel Chi-square and 
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Poisson tests for association were used to test for trends in the data on a per ovary or lesion 
frequency basis, respectively.  
 
RESULTS 
eYFP expression is strongly induced in oviductal epithelium but not OSE following 
transient TAM treatment of Ovgp1-iCreERT2;R26RLSL-eYFP mice   
We previously showed, using immunohistochemical (IHC) staining, that OVGP1 is strongly 
expressed by the oviductal epithelium, but is absent in the ovarian stroma and ovarian surface 
epithelium and other organs such as liver, lung, pancreas, lymph node and spleen [18].  In our 
model system, in OVGP1-expressing cells Cre recombinase function can be transiently 
activated by treating mice with TAM.  Cre-mediated recombination removes transcription 
inhibitory elements, resulting in expression of the eYFP reporter in cells expressing OVGP1.  
This eYFP expression is retained over the lifetime of the cells and in all of their subsequent 
progeny.  Transient treatment of double transgenic Ovgp1-iCreERT2;R26RLSL-eYFP  mice with 
TAM, but not with vehicle, results in strong expression of eYFP in the oviductal epithelium, but 
not in the ovarian surface epithelium, the underlying ovarian stroma, or adjacent soft tissues 
(Figure 1A–D and [18]).   
 
Endosalpingiosis-like lesions are present in a subset of ovaries from genetically 
engineered mice   
In our prior studies aimed at developing various genetically engineered mouse models of 
ovarian and oviductal carcinomas [18,20–22], we occasionally identified endosalpingiosis-like 
lesions in mouse ovaries.  The lesions which we refer to hereafter as endosalpingiosis are 
typically characterized by small glands or cysts near the ovarian hilum (Figure 2A), though 
occasional glands/cysts are present in the subserosal ovarian cortex distant from the hilum 
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(Figure 2B).  The inclusion cysts/glands are occasionally multiple (Figure 2C) and are lined by 
OVGP1-positive columnar epithelium including secretory and ciliated cells of the type present 
in normal oviductal epithelium (Figure 2D).  The epithelium lining the glands/cysts is focally 
positive for tubulin, which marks ciliated cells (Figure 2E), and PAX8 which preferentially marks 
secretory cells (Figure 2F).   
 
Mouse ovarian endosalpingiosis lesions do not represent rete ovarii 
As noted above, we observed that most ovarian endosalpingiosis lesions in adult mice (with or 
without superovulation) were located near the hilum or had at least one side of the cyst wall 
facing the hilum when the cyst was too large to determine its location with certainty.  Their 
predominantly hilar location suggests the possibility that the lesions represent mesonephric 
duct remnants (rete anlage), which have been proposed as an origin of cysts and proliferative 
epithelial lesions in the mouse ovary and can occasionally show cilia [23].  We wished to 
determine whether the mouse endosalpingiosis lesions in ovaries might represent dilated rete 
ovarii.  An example of extra-ovarian rete in periadnexal soft tissue adjacent to the oviduct and 
ovary is shown in Figure 3.  We found the extra-ovarian rete (Figure 3A, B) is PAX8 positive 
(Figure 3C, D) and OVGP1 negative (Figure 3E, F), while all of the endosalpingiosis lesions 
were OVGP1 positive.  These findings indicate the ovarian endosalpingiosis lesions in the mice 
do not likely represent dilated rete ovarii.  
 
Ovarian endosalpingiosis in Ovgp1-iCreERT2;R26RLSL-eYFP  mice does not increase with 
age  
We initially evaluated a cohort of mice (n=18, 36 ovaries) only 2 days after the sequential 3-day 
treatment of mice with TAM.  By light microscopic analysis, endosalpingiosis lesions were 
found in 11.1% (2 of 18) animals; an example is shown in Figure 4A,B.  As expected, the 
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lesions expressed OVGP1, based on IHC staining (Figure 4C,D).   Interestingly, cells in the 
ovarian endosalpingiosis lesions were also eYFP positive (Figure 4E,F); eYFP positive cells 
from the oviduct might have detached and subsequently implanted in the ovary within only 2 
days of TAM treatment (tubal escape).  However, based on the number of cells in the lesions 
and the very short time post-TAM, it is much more likely that the OVGP1 positive cells were 
already resident in the ovary at the time of TAM treatment (Müllerian metaplasia).  If “tubal 
escape” were the dominant mechanism underlying mouse ovarian endosalpingiosis, we had 
predicted that eYFP positive lesions would accumulate in double transgenic Ovgp1-
iCreERT2;R26RLSL-eYFP mice as they aged. Cohorts of Ovgp1-iCreERT2;R26RLSL-eYFP  mice were 
given TAM injections at 6–8 weeks of age and then sacrificed 1 wk (n=12), 1 mo (n=9), 6 mo 
(n=20) and 12 mo (n=20) after transient TAM treatment.  Both ovaries and oviducts from each 
animal were harvested and sectioned in their entirety as described above.  OVGP1/eYFP 
double-positive endosalpingiosis lesions were identified in 8.3%, 11.1%, 10% and 20% of 
animals in these cohorts, respectively (Table 1).  None of the mice had endosalpingiosis in both 
ovaries and the number of lesions present in a given ovary was two or fewer.  Although there 
was a trend toward increased endosalpingiosis (e.g., between 1 wk and 12 mo post-TAM), this 
was not statistically significant (P = 0.51 Mantel-Haenszel Chi-square test of association), and 
no time points were significantly different from the results for day 2 mice (Table 1, two-sided 
Fisher Exact tests all gave P > 0.6).  No OVGP1 positive/eYFP negative or eYFP 
positive/OVGP1 negative lesions were identified. 
 
Ovarian endosalpingiosis in Ovgp1-iCreERT2;R26RLSL-eYFP  mice does not increase with 
superovulation  
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The “tubal escape” hypothesis also predicts that superovulated mice will harbor more ovarian 
endosalpingiosis than control mice, and that these lesions will accumulate over time.  To test 
this experimentally, littermates of mice described above were used to generate additional 
cohorts of mice that underwent up to 5 cycles of superovulation and these cohorts were 
sacrificed at 1 mo (n=8), 6 mo (n=22) and 12 mon (n=18) post-TAM.   Endosalpingiosis lesions 
were identified in 25%, 18.2%, and 11.1% of animals in these cohorts, respectively, indicating 
that endosalpingiosis does not accumulate in superovulated mice and providing further 
evidence that mouse endosalpingiosis does not accumulate with age (Table 1, P = 1.0 for the 4 
by 2 table that included day 2 control mice, Mantel-Haenszel Chi-square test of association), 
nor did mice undergoing superovulation have endosalpingiosis more frequently than control 
mice at the same time points (P > 0.5 for all three time points, two-sided Fisher Exact test).  All 
of the lesions identified were OVGP1/eYFP double-positive.  One mouse had endosalpingiosis 
in both ovaries and the maximum number of lesions in a given ovary was three (seen in one 
mouse).  Overall, ovarian endosalpingiosis was identified in 14.2% (18 of 127) of the adult mice 
included in our study (Table 1).   
 
Mouse ovarian endosalpingiosis is observed before sexual maturation 
In order to determine whether mouse ovarian endosalpingiosis lesions can occur prior to sexual 
maturity (i.e., requires ovulation), and whether OVGP1-positive cells are already present in the 
ovaries of prepubertal mice, a cohort (n=30) of 4 wk old mice was treated with TAM and 
sacrificed 3–4 days later.  This time point precedes sexual maturation [24].  In this cohort, 
ovarian endosalpingiosis was identified in 2 of 30 animals (6.7%).  Comparison of 
endosalpingiosis frequency in this group to the day 2 mice gives P = 0.62 (two-sided Fisher 
Exact test). These lesions were also OVGP1/eYFP double positive, and were located in the 
11 
 This article is protected by copyright. All rights reserved.
ovarian medulla near the hilum.  These results suggest that mouse ovarian endosalpingiosis is 
present early in post-natal development, does not require ovulation, and that OVGP1 




Our studies show that mice acquire ovarian endosalpingiosis-like lesions, and that these 
lesions do not likely arise as a consequence of detachment from the oviduct followed by 
implantation in the ovary.   If an implantation mechanism for endosalpingiosis is not supported 
by our data, what other mechanisms should be considered?  Presumably, ectopic tubal-type 
epithelium could arise from differentiation of resident pluripotent or multipotent stem-like cells, 
or as a consequence of metaplasia (trans-differentiation), in which one type of differentiated 
cell changes to another cell type  [25].  In either case, this differentiation “switch” would likely 
depend on the appropriate local and/or systemic hormonal milieu, as endosalpingiosis is 
uncommon in human males [26,27].  However, our identification of ovarian endosalpingiosis in 
a subset of pre-pubertal mice suggests that development of endosalpingiosis is not dependent 
on post-pubertal hormones, at least in mice.  The propensity for endosalpingiosis-like lesions in 
mice to arise near the ovarian hilum could reflect tubal-type differentiation of resident cells with 
stem-like properties that are enriched in this region [28].  Specifically, Flesken-Nikitin and 
colleagues found that the hilar/junctional area between the OSE, mesothelium and tubal 
(oviductal) epithelium is enriched for cells that express stem and/or progenitor cell markers 
such as ALDH1, LGR5, LEF1, CD133 and CK6B, and display stem cell properties ex vivo and 
in vivo.  Hence, under the right conditions, these cells could potentially acquire tubal-type 
differentiation manifest as glands and cysts that initiate in the ovarian hilum.  Presumably, this 
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tubal type epithelium was already present in the ovaries in a subset of mice, before activation 
of the eYFP reporter in OVGP1-positive cells induced by TAM.   
 
Importantly, mice and humans have anatomical and biological differences such that 
conclusions drawn in one mammalian system may not apply to the other and we cannot 
exclude detachment and implantation of FTE as an important underlying mechanism of 
endosalpingiosis in humans.  However, the occasional identification of endosalpingiosis in 
human males [29], argues against “tubal escape” as the sole mechanism underlying 
endosalpingiosis in women.   Interestingly, while ovarian endosalpingiosis in the mouse might 
be expected to arise from either implantation or Müllerian metaplasia, endosalpingiosis outside 
the ovary, e.g., the omentum, presumably occurs only via the latter mechanism, since detached 
FTE from the oviduct cannot readily access the peritoneal space in mice due to the presence of 
the murine ovarian bursa.  This contrasts with the situation in humans, in which detached FTE 
has direct access to the peritoneal cavity.  We have occasionally observed endosalpingiosis-
like lesions outside of the ovary in mice (Supplemental Figure 1), but this has been in the 
context of oviductal tumor development in Ovgp1-iCreERT2 mice also carrying tumor 
suppressor genes alleles that undergo recombination following TAM treatment.  Though this 
finding would provide further support for stem cell differentiation or metaplasia rather than tubal 
escape as the primary mechanism underlying endosalpingiosis in mice, more in-depth analysis 
of endosalpingiosis-like lesions in extra-ovarian locations are needed before meaningful 
conclusions can be drawn.   
 
Our data fail to support detachment and implantation of oviductal epithelium as a major 
mechanism underlying endosalpingiosis in mice.  In 2005, Bristol-Gould and colleagues 
described a mouse model of ovarian endosalpingiosis in which the Müllerian-inhibiting 
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substance (MIS) promoter was used to drive expression of a dominant-negative form of 
SMAD2 [16].  In this model system, female mice develop ovarian endosalpingiosis and the 
authors proposed that the lesions likely arise from Müllerian epithelium, though the origin of the 
lesional cells (e.g., oviduct, endometrium, rete ovarii, or OSE) was not determined.  More 
recently, Gendronneau et al reported ovarian “inclusion cysts reminiscent of human 
endosalpingiosis” in Hoxa5-/- female mice [17].   The epithelium lining the cysts was shown to 
express WT1 and PAX8, consistent with Müllerian tubal-type differentiation.  Other studies 
have described analyses of serous epithelial inclusion cysts in mouse ovaries in relation to age, 
pregnancy, and/or number of ovulations [14,15].  Interestingly, Burdette and colleagues studied 
ovarian “inclusion” cysts with features resembling endosalpingiosis in chronically superovulated 
wild-type CD1 mice and CD1 mice carrying a dominant negative Smad2 transgene under 
control of the MISIIR promoter.  They found that the number of ovarian “inclusion cysts” was 
not significantly different between superovulated and control mice in either the wild-type or 
transgenic groups [15].  While they demonstrated that the observed cysts were epithelial (CK8 
positive), they were not able to identify the origin of the cysts due to lack of specific markers. 
These prior studies by Gendronneau and Burdette utilized transgenic animals with genetically 
engineered alleles of powerful modulators of cell fate and differentiation. An important strength 
of the model described here is the use of lineage tracing with an eYFP reporter that is not 
predicted to alter cell identity or differentiation capacity.  However, we cannot completely 
exclude the possibility that eYFP itself has toxic effects in some microenvironmental contexts, 
and this may have limited our ability to observe an accumulation of eYFP+ lesions in ovarian 
locations. Importantly, others have shown that YFP, but not GFP, provides stable fluorescent 
marking of rodent hepatic adult stem cells [30].  It also bears noting that we observed eYFP+ 
lesions up to 12 months after TAM treatment, suggesting that the presence of intracellular 
eYFP is not inherently toxic to cells.  
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Finally, Tan et al reported that cysts resembling benign serous inclusion cysts in humans 
increase with age and with incessant ovulation in out-bred Swiss Webster mice, but proposed 
the OSE rather than the oviductal epithelium as the likely origin of the cysts [14].  Additional 
approaches and experimental work will be needed to address the relative contribution of the 
OSE to endosalpingiosis-like lesions in the mouse. Our work confirms earlier findings in mice 
and provides data suggesting that the “inclusion” glands and cysts in the mouse ovary with 
features resembling endosalpingiosis do not arise as a consequence of oviductal epithelial 
detachment and subsequent implantation in the ovary.    
 
ACKNOWLEDGEMENTS 
Research reported in this publication was supported by the National Cancer Institute of the 
National Institutes of Health under Award Numbers P30CA046592 (KRC, ERF, RK) including 
use of the Transgenic Animal Models and Biostatistics, Analytics & Bioinformatics Shared 
Resources, and R01CA188516 (KRC, YZ, RK).  
 
AUTHOR CONTRIBUTIONS STATEMENT 
 
YW, MS, YZ, CT, KM, RK, DCC, ERF, and KRC conceived experiments and/or analyzed data.  
YW, MS, CT, and YZ conceived and carried out experiments.  All authors were involved in 
writing the paper and had final approval of the submitted version.    
15 
 This article is protected by copyright. All rights reserved.
REFERENCES 
1. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed 
Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451–
456. 
2. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous 
carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3–9. 
3. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic 
serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161–169. 
4. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in 
the distal fallopian tube. J Pathol 2007; 211: 26–35. 
5. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early 
adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 
230–236. 
6. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of 
tubal origin? Am J Surg Pathol 2010; 34: 1407–1416. 
7. Yates MS, Meyer LA, Deavers MT, et al. Microscopic and early-stage ovarian cancers in BRCA1/2 
mutation carriers: building a model for early BRCA-associated tumorigenesis. Cancer prevention 
research 2011; 4: 463–470. 
8. Prentice L, Stewart A, Mohiuddin S, et al. What is endosalpingiosis? Fertil Steril 2012; 98: 942–
947. 
9. Vang R, Shih I-M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous 
neoplasms. Histopathology 2013; 62: 44–58. 
16 
 This article is protected by copyright. All rights reserved.
10. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed 
unifying theory. Am J Surg Pathol 2010; 34: 433–443. 
11. McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and 
complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 
210: 471 e471–411. 
12. Holman LL, Friedman S, Daniels MS, et al. Acceptability of prophylactic salpingectomy with 
delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol 
2014; 133: 283–286. 
13. Nebgen DR, Hurteau J, Holman LL, et al. Bilateral salpingectomy with delayed oophorectomy for 
ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol 
2018; 150: 79–84. 
14. Tan OL, Hurst PR, Fleming JS. Location of inclusion cysts in mouse ovaries in relation to age, 
pregnancy, and total ovulation number: implications for ovarian cancer? J Pathol 2005; 205: 
483–490. 
15. Burdette JE, Oliver RM, Ulyanov V, et al. Ovarian epithelial inclusion cysts in chronically 
superovulated CD1 and Smad2 dominant-negative mice. Endocrinology 2007; 148: 3595–3604. 
16. Bristol-Gould SK, Hutten CG, Sturgis C, et al. The development of a mouse model of ovarian 
endosalpingiosis. Endocrinology 2005; 146: 5228–5236. 
17. Gendronneau G, Boucherat O, Aubin J, et al. The loss of Hoxa5 function causes estrous 
acyclicity and ovarian epithelial inclusion cysts. Endocrinology 2012; 153: 1484–1497. 
18. Wu R, Zhai Y, Kuick R, et al. Impact of oviductal versus ovarian epithelial cell of origin on ovarian 
endometrioid carcinoma phenotype in the mouse. J Pathol 2016; 240: 341–351. 
17 
 This article is protected by copyright. All rights reserved.
19. Choi KH, Joo BS, Sun ST, et al. Administration of visfatin during superovulation improves 
developmental competency of oocytes and fertility potential in aged female mice. Fertil Steril 
2012; 97: 1234–1241 e1231–1233. 
20. Zhai Y, Wu R, Kuick R, et al. High-grade serous carcinomas arise in the mouse oviduct via 
defects linked to the human disease.  J Pathol 2017; 243: 16–25. 
21. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid 
adenocarcinoma based on somatic defects in the Wnt/B-catanin and PI3K/Pten signaling 
pathways. Cancer Cell 2007; 11: 321–333. 
22. Zhai Y, Kuick R, Tipton C, et al. Arid1a inactivation in an Apc- and Pten-defective mouse ovarian 
cancer model enhances epithelial differentiation and prolongs survival. J Pathol 2015; 238: 21–
30. 
23. Long GG. Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial 
lesions in the mouse ovary. Toxicol Pathol 2002; 30: 592–598. 
24. Dutta S, Sengupta P. Men and mice: Relating their ages. Life Sci 2016; 152: 244–248. 
25. Karnezis AN, Cho KR, Gilks CB, et al. The disparate origins of ovarian cancers:  pathogenesis and 
prevention strategies. Nature Rev Cancer 2016; 17: 65–74. 
26. Zinsser KR, Wheeler JE. Endosalpingiosis in the omentum: a study of autopsy and surgical 
material. Am J Surg Pathol 1982; 6: 109–117. 
27. Irving J, Clement PB. Diseases of the Peritoneum. In: Blaustein's Pathology of the Female 
Genital Tract. 6th ed. Kurman RJ, Ellenson LH, Ronnett B, (eds). Springer: New York, 2011. 
28. Flesken-Nikitin A, Hwang CI, Cheng CY, et al. Ovarian surface epithelium at the junction area 
contains a cancer-prone stem cell niche. Nature 2013; 495: 241–245. 
18 
 This article is protected by copyright. All rights reserved.
29. Gallan AJ, Antic T. Benign mullerian glandular inclusions in men undergoing pelvic lymph node 
dissection. Hum Pathol 2016; 57: 136–139. 
30. Taghizadeh RR, Sherley JL. CFP and YFP, but not GFP, provide stable fluorescent marking of rat 








Figure 1.  Tamoxifen induces eYFP expression in the oviductal epithelium of Ovgp1-
iCreERT2;R26RLSL-eYFP mice.  Oviductal expression of eYFP (seen as green fluorescence) is 
induced by transient treatment with TAM (A) but not vehicle (B) in Ovgp1-iCreERT2;R26RLSL-eYFP 
double transgenic mice.  Mouse oviducts are indicated by white arrows, ovaries by white arrow 
heads and uterine horns by white stars.  Representative photomicrographs showing eYFP 
expression in the oviductal epithelium of TAM-treated mouse based on immunohistochemical 
staining (C), but not in the vehicle treated mouse (D). 
 
 
Figure 2. Representative examples of ovarian endosalpingiosis in Ovgp1-
iCreERT2;R26RLSL-eYFP mice. Ovarian endosalpingiosis lesions (indicated by black stars), are 
usually located in the medulla near ovarian hilum (A), but are occasionally found in the ovarian 
cortex (B). Some ovaries harbor more than one lesion (C). The epithelium lining 
endosalpingiotic glands and cysts is OVGP1 positive (inset) and includes both secretory and 
ciliated cells (D), with ciliated cells expressing tubulin (E) and secretory cells preferentially 
expressing PAX8 (F, inset shows high-magnification).   Note the internal positive control for 
PAX8 (normal oviduct) in lower left corner of panel F at black arrow.  Black arrowheads indicate 
ciliated cells in panels D and E.  Scale bars:  200 µm (panels A, B, F); 100 µm (panel C); 50 µm 
(panels D, E).   
 
Figure 3. Endosalpingiosis lesions in Ovgp1-iCreERT2;R26RLSL-eYFP mice are different 
from rete ovarii. Although extra-ovarian rete also forms glands lined by columnar cells (A) that 
express PAX8 (C), the rete does not express OVGP1 (E).  High magnifications of boxed areas 
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in A, C, and E are shown in B, D, F, respectively. Note the internal positive control for detection 
of PAX8 and OVGP1 expression (normal oviduct at black arrows) in lower left corners of panels 
C and E.  Scale bars:  200 µm (panels A, C, E); 50 µm (panels B, D, F). 
 
Figure 4. Ovarian endosalpingiosis lesions express both OVGP1 and eYFP in TAM-
treated Ovgp1-iCreERT2;R26RLSL-eYFP mice.  A representative example of endosalpingiosis in 
a TAM-treated double transgenic mouse is shown: H&E stained section (A), and adjacent 
sections immunohistochemically stained for OVGP1 (C) and eYFP (E).  High magnifications of 
boxed areas in panels A, C, and E are shown in panels B, D, and F, respectively. Note the 
internal positive control for detection of OVGP1 and eYFP expression (normal oviduct at black 
arrows) in lower left corners of panels C and E.  Scale bars:  200 µm (panels A, C, E); 50 µm 
(panels B, D, F). 
 
 
SUPPLEMENTARY MATERIAL ONLINE 
 
Supplementary materials and methods  NO 
 
Supplementary figure legends  NO, the legend is embedded 
 
 
Figure S1. Endosalpingiosis-like lesions are occasionally observed in the omentum  
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Table 1. Incidence of endosalpingiosis in mice over time, with and without superovulation 







No superovulation  Superovulation   



































2 days  2/18 11.1%      
 
1 week 1/12  8.3% 1.00      
1 month 1/9  11.1% 1.00  2/8  25.0%  0.56 0.58 
6 months 2/20  10.0% 1.00  4/22  18.2% 0.67 0.67 
12 months 4/20  20.0% 0.66  2/18  11.1% 1.00 0.66 
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